The number of visits to a doctor’s office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

Curidium Medica Plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, announced on May 14th it has developed a blood diagnostic test that can sub-classify patients with schizophrenia/bipolar disorder into one of four subgroups.